Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?

Valentina Indio; Annalisa Astolfi; Milena Urbini; Margherita Nannini; Maria A Pantaleo

doi:10.2217/pgs-2019-0173

Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?

Pharmacogenomics. 2020 Mar;21(4):231-234. doi: 10.2217/pgs-2019-0173. Epub 2020 Jan 24.

Authors

Valentina Indio¹, Annalisa Astolfi^{1

2}, Milena Urbini¹, Margherita Nannini^{1

3}, Maria A Pantaleo^{1

3}

Affiliations

¹ "Giorgio Prodi" Cancer Research Center (CIRC), University of Bologna, Bologna, Italy.
² Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.
³ Department of Specialized, Experimental & Diagnostic Medicine, University of Bologna, Bologna, Italy.

PMID: 31973655
DOI: 10.2217/pgs-2019-0173

No abstract available

Keywords: PD-L1 expression; CD4+ T cells; CD8+ T cells; IFN-γ signaling pathway; M2 macrophages; checkpoint inhibitors; gastrointestinal stromal tumors (GISTs); immunotherapy; tumor-infiltrating lymphocytes (TILs).

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Disease Progression
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / genetics*
Humans
Imatinib Mesylate / therapeutic use
Immune Checkpoint Inhibitors / therapeutic use*
Phenylurea Compounds / therapeutic use
Prognosis
Protein Kinase Inhibitors / therapeutic use
Pyridines / therapeutic use
Sunitinib / therapeutic use

Substances

Immune Checkpoint Inhibitors
Phenylurea Compounds
Protein Kinase Inhibitors
Pyridines
regorafenib
Imatinib Mesylate
Sunitinib